Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant.
HIV treatment
TAF monotherapy
implantable drug delivery
long-acting TAF
viral load
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 Oct 2020
17 Oct 2020
Historique:
received:
29
09
2020
revised:
12
10
2020
accepted:
14
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
HIV-1 is a chronic disease managed by strictly adhering to daily antiretroviral therapy (ART). However, not all people living with HIV-1 have access to ART, and those with access may not adhere to treatment regimens increasing viral load and disease progression. Here, a subcutaneous nanofluidic implant was used as a long-acting (LA) drug delivery platform to address these issues. The device was loaded with tenofovir alafenamide (TAF) and implanted in treatment-naïve simian HIV (SHIV)-positive nonhuman primates (NHP) for a month. We monitored intracellular tenofovir-diphosphate (TFV-DP) concentration in the target cells, peripheral blood mononuclear cells (PBMC). The concentrations of TFV-DP were maintained at a median of 391.0 fmol/10
Identifiants
pubmed: 33080776
pii: pharmaceutics12100981
doi: 10.3390/pharmaceutics12100981
pmc: PMC7590004
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI120749
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01GM127558
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : R01AI120749
Organisme : Consejo Nacional de Ciencia y Tecnología
ID : Fellowship
Organisme : NIGMS NIH HHS
ID : R01 GM127558
Pays : United States
Organisme : Gilead Sciences
ID : SRA
Références
Int J Pharm. 2020 Sep 25;587:119623
pubmed: 32663582
J Control Release. 2019 Jul 28;306:89-96
pubmed: 31136811
Sci Transl Med. 2012 Sep 12;4(151):151ra125
pubmed: 22972843
Retrovirology. 2010 Oct 13;7:88
pubmed: 20942954
Int J Obes (Lond). 2016 Nov;40(11):1776-1783
pubmed: 27460601
Antimicrob Agents Chemother. 2001 May;45(5):1438-43
pubmed: 11302807
Antimicrob Agents Chemother. 2015 Jul;59(7):3913-9
pubmed: 25896688
J Leukoc Biol. 2015 Dec;98(6):953-62
pubmed: 26168797
J Biomed Mater Res A. 2003 Dec 1;67(3):856-67
pubmed: 14613234
Lab Chip. 2020 May 5;20(9):1562-1576
pubmed: 32249279
ACS Appl Mater Interfaces. 2020 Mar 11;12(10):12246-12255
pubmed: 32068385
J Med Primatol. 2007 Aug;36(4-5):254-65
pubmed: 17669214
Nat Commun. 2018 Apr 27;9(1):1682
pubmed: 29703954
J Control Release. 2018 Sep 28;286:315-325
pubmed: 30092254
J Sex Med. 2015 Jun;12(6):1375-80
pubmed: 25930087
Lab Chip. 2019 Jun 25;19(13):2192-2204
pubmed: 31169840
Lancet. 2017 Sep 23;390(10101):1499-1510
pubmed: 28750935
Pharmaceutics. 2020 Jul 19;12(7):
pubmed: 32707665
Biomed Microdevices. 2019 May 18;21(2):47
pubmed: 31104136
Lancet. 2001 Nov 24;358(9295):1760-5
pubmed: 11734232
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30012772
J Antimicrob Chemother. 2014 May;69(5):1362-9
pubmed: 24508897
J Pharm Biomed Anal. 2011 Sep 10;56(2):390-401
pubmed: 21715120
J Int AIDS Soc. 2019 Nov;22(11):e25405
pubmed: 31692269
J Control Release. 2013 Dec 28;172(3):1011-9
pubmed: 24095805
J Control Release. 2018 Sep 10;285:23-34
pubmed: 30008369
Lancet HIV. 2020 Mar;7(3):e164-e172
pubmed: 31911147
Biomed Microdevices. 2013 Apr;15(2):353-68
pubmed: 23319268
Pharm Res. 2016 Jul;33(7):1649-56
pubmed: 26975357
Curr Opin HIV AIDS. 2013 Nov;8(6):565-71
pubmed: 24100877
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55
pubmed: 23807155
J Acquir Immune Defic Syndr. 2014 May 1;66(1):80-9
pubmed: 24326608
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31871073
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12
pubmed: 24469825
Pharmaceutics. 2019 Jul 04;11(7):
pubmed: 31277461
Drug Deliv Transl Res. 2015 Dec;5(6):531-9
pubmed: 26315144
Nanomedicine (Lond). 2016;11(5):545-64
pubmed: 26892323
J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S14-8
pubmed: 17525686
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
ACS Nano. 2011 Dec 27;5(12):9382-91
pubmed: 22032773
ACS Appl Mater Interfaces. 2018 Sep 26;10(38):32233-32238
pubmed: 30185043
Nanomedicine. 2019 Feb;16:1-9
pubmed: 30468870